Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000315066-24-001033.pdf
0000315066-24-001033.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0000902219-24-000050.pdf
0000902219-24-000050.rtf
0000902219-24-000050.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-24-001931.pdf
0001415889-24-001931.rtf
0001415889-24-001931.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001968582-24-000049.pdf
0001968582-24-000049.rtf
0001968582-24-000049.xls
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001086364-24-002011.pdf
0001086364-24-002011.rtf
SC 13G/A

An amendment to the SC 13G filing

 View HTML
0001104659-24-002863.pdf
0001104659-24-002863.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-24-002075.pdf
0001104659-24-002075.rtf
0001104659-24-002075.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-016929.pdf
0001415889-23-016929.rtf
0001415889-23-016929.xls
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

 View HTML
0001950047-23-006422.pdf
0001950047-23-006422.rtf
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-016721.pdf
0001415889-23-016721.rtf
0001415889-23-016721.xls